Good Shroom Co Inc (TSE:MUSH)
:MUSH
Top Page
Good Shroom Co Inc
(MUSH)
Select Model
Select Model
Rating:54Neutral
Price Target:
C$0.14
▼(-2.86% Downside)
Action:ReiteratedDate:02/25/26
The score is held back primarily by weak profitability and pressured equity despite strong revenue growth and improved (but potentially volatile) cash flow. Technicals provide meaningful support due to a clear uptrend and positive momentum, while valuation remains constrained by negative earnings and no dividend.
Positive Factors
Strong revenue growth
Sustained triple‑digit TTM revenue growth shows durable demand expansion and scale potential in the specialty drug market. Over 2–6 months this top‑line momentum supports capacity utilization, negotiation leverage with suppliers, and the opportunity to spread fixed costs as the business scales.
Negative Factors
Low gross margin
A low gross margin (~14%) limits the company’s ability to absorb SG&A, R&D and unexpected costs while remaining profitable. Over 2–6 months structural margin pressure constrains operating leverage, making sustainable profitability harder without product mix improvement or cost structural changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Sustained triple‑digit TTM revenue growth shows durable demand expansion and scale potential in the specialty drug market. Over 2–6 months this top‑line momentum supports capacity utilization, negotiation leverage with suppliers, and the opportunity to spread fixed costs as the business scales.
Read all positive factors
Good Shroom Co Inc (MUSH) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$8.27M
Dividend YieldN/A
Average Volume (3M)19.64K
Price to Earnings (P/E)11.3
Beta (1Y)1.29
Revenue Growth-26.71%
EPS Growth-988.89%
CountryCA
EmployeesN/A
SectorConsumer Defensive
Sector Strength42
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding51,674,683
10 Day Avg. Volume26,649
30 Day Avg. Volume19,637
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)16.94
Price to Sales (P/S)1.37
P/FCF Ratio19.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Good Shroom Co Inc Business Overview & Revenue Model
Company Description
Mercanto Holdings Inc. engages in the development, manufacture, and sale of instant wellness beverages. It includes traditional cannabis, probiotics, and functional mushrooms. Its brands include Velada, Nordique Royale, and Teonan. The company was...
How the Company Makes Money
null...
Good Shroom Co Inc Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
44
Neutral
Cash Flow
56
Neutral
| Breakdown | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.00M | 3.89M | 3.16M | 1.22M | 242.13K |
| Gross Profit | 621.69K | 1.23M | 665.12K | 228.64K | 61.90K |
| EBITDA | -390.16K | 66.24K | -427.19K | -1.56M | -3.56M |
| Net Income | -412.31K | 40.60K | -452.14K | -1.63M | -3.85M |
Balance Sheet | |||||
| Total Assets | 1.02M | 1.48M | 1.44M | 1.64M | 2.30M |
| Cash, Cash Equivalents and Short-Term Investments | 394.97K | 202.37K | 378.42K | 751.55K | 1.69M |
| Total Debt | 0.00 | 17.53K | 74.06K | 207.78K | 258.46K |
| Total Liabilities | 778.53K | 899.77K | 986.48K | 881.55K | 495.21K |
| Stockholders Equity | 242.01K | 583.10K | 457.57K | 762.81K | 1.80M |
Cash Flow | |||||
| Free Cash Flow | 210.60K | -148.04K | -355.13K | -777.78K | -1.73M |
| Operating Cash Flow | 210.60K | -148.04K | -355.13K | -777.78K | -1.71M |
| Investing Cash Flow | 0.00 | 0.00 | 70.00K | 0.00 | 2.58M |
| Financing Cash Flow | -18.00K | -28.02K | -18.00K | -160.00K | 247.13K |
Good Shroom Co Inc Technical Analysis
Positive
0.14
Price Trends
0.15
Positive
0.14
Positive
0.11
Positive
Market Momentum
>-0.01
Negative
56.56
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MUSH, the sentiment is Positive. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.15, and above the 200-day MA of 0.11, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 56.56 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MUSH.
Good Shroom Co Inc Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
54 Neutral | C$8.27M | 11.26 | -99.55% | ― | -26.71% | -988.89% | |
49 Neutral | C$20.21M | -2.55 | ― | ― | -100.00% | -8.70% | |
47 Neutral | C$14.65M | -4.56 | 899.59% | ― | ― | -80.42% | |
45 Neutral | C$9.23M | 5.19 | ― | ― | 15.64% | 58.47% |
* Consumer Defensive Sector Average
TSE:MUSH
Good Shroom Co Inc
0.16
0.10
166.67%
TSE:RVV
Revive Therapeutics
0.04
0.02
133.33%
TSE:PCLO
PharmaCielo
0.06
0.02
33.33%
TSE:SPR
Sproutly Canada
0.02
0.00
0.00%
TSE:LOBE
Lobe Sciences
0.08
0.05
200.00%
Good Shroom Co Inc Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Mercanto’s Quebec Vape Launch Drives Revenue Surge and Return to Profit
Positive
Feb 24, 2026
Mercanto Holdings Inc. reported that its late-quarter entry into Quebec’s new vape cartridge category, with three cartridge SKUs and a branded battery, has rapidly become a key growth engine. The launch, which coincided with the December hol...
Business Operations and StrategyFinancial Disclosures
Mercanto Holdings Posts Higher Q1 Revenue as It Shifts Toward High-Growth Cannabis Categories
Positive
Dec 29, 2025
Mercanto Holdings Inc. reported first-quarter fiscal 2026 revenue of $900,013, up 9% year over year, and net revenue of $784,529 after excise taxes, while posting a net loss of $146,213 as gross margins were temporarily pressured by product mix. M...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.